B of A Securities analyst Steve Byrne downgrades Univar Solns (NYSE:UNVR) from Buy to Underperform.
CASI Pharmaceuticals Announces Exit Of Juventas Investment To Strengthen Balance Sheet
CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products ("CASI"), today announced that CASI
